ESC 365 - Introduction - SGLT2 inhibition in diabetes and heart failure: discuss the evidence.

ESC Premium Access

Introduction - SGLT2 inhibition in diabetes and heart failure: discuss the evidence.

Session: SGLT2 inhibition in diabetes and heart failure: discuss the evidence

Topic: Diabetes management

Speaker: Doctor D. Fitchett (Toronto, CA)

Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Doctor David Fitchett

St. Michael's Hospital, Toronto (Canada)

18 presentations

0 follower

2 more presentations in this session

SGLT2 inhibition: exploring the evidence in diabetes and heart failure.

Speaker: Professor J. McMurray (Glasgow, GB)

Access

Interactive discussion: what are the implications of SGLT2 inhibition in HF patients with diabetes?

Speaker: Doctor D. Fitchett (Toronto, CA) Professor J. McMurray (Glasgow, GB)

Access

Access the full session

SGLT2 inhibition in diabetes and heart failure: discuss the evidence

Speakers: Doctor D. Fitchett, Professor J. McMurray, Doctor D. Fitchett, Professor J. McMurray

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources